A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Experimental Nuclear Medicine Meets Tumor Biology
2022
Pharmaceuticals
Personalized treatment of cancer patients demands specific and validated biomarkers for tumor diagnosis and therapy. The development and validation of such require translational preclinical models that recapitulate human diseases as accurately as possible. Moreover, there is a need for convergence of different (pre)clinical disciplines that openly share their knowledge and methodologies. This review sheds light on the differential perception of biomarkers and gives an overview of currently used
doi:10.3390/ph15020227
pmid:35215337
pmcid:PMC8878163
fatcat:xjh7itwykzdphduucihakosqou